We have just released a list of 10 stocks that are performing well even with uncertain market feelings. In this article, we will examine how Baxter International Inc. (NYSE:BAX) compares to other stocks that are also doing well despite mixed market sentiment. The stock market started the week with its first trading day on a […]
Scott Baxter, the Chair, President, and CEO of Kontoor Brands, appears on 'Mad Money' with host Jim Cramer to discuss the acquisition of Helly Hansen, their global business strategies, and other topics.
Baxter has announced fourth-quarter results that are better than anticipated. However, the company's gross and operating margins have decreased.
The main figures for Baxter (BAX) provide an overview of the company's performance for the quarter that ended in December 2024. However, it could be helpful to compare some important metrics with Wall Street predictions and the results from the same period last year.
On Thursday, Baxter International predicted that its profits for 2025 would exceed Wall Street's expectations, thanks to robust sales of its medical devices. This news caused the company's shares to rise by 7% in premarket trading.
Baxter International Inc., a leading company in medical technology, will speak at the 46th Annual Institutional Investors Conference hosted by Raymond James & Associates on March 3, 2025. Joel Grade, the company's CFO, is set to present at 1:05 p.m. Eastern Time. People can watch the live webcast of the presentation on Baxter's website, and it will be available for replay until August 30, 2025.
Baxter may have encountered challenges in the fourth quarter due to Hurricane Helene. Nevertheless, the company anticipates that growth in infusion therapies, pharmaceuticals, and patient support systems will help it bounce back.
Baxter International, a company that makes medical products, announced on Monday that its CEO, José Almeida, will retire right away after almost ten years in the role.
In the stock market, not every stock performs well. Some stocks end up struggling and are affected by the changing feelings of investors.
BAX has introduced five new injectable products in the United States, which enhances its pharmaceutical business in the country. This move helps to solidify BAX's presence in the U.S. market.